OptiBiotix Health PLC

06 July 2021

Opti B i otix Health plc

(" Opti Bi o t ix" or the "Company")

Further sales expansion in Asia

New Exclusive Distribution deal for CholBiome(R) in South Korea

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, a nn o unces that its wholly-owned subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has entered a exclusive disbution deal with INSCOBEE INC ("Inscobee") for CholBiome(R) in the Republic of Korea.

Inscobee was established in 1970 and is listed on Korea's major stock market KOSPI since 1985. Its business activities consist of four fast growing business fields: the Smart grid, Mobile Virtual Network Operation, Cosmetics, and Bio-Tech, which includes its pharmaceutical, neutraceuticals, and supplement products with distribution in domestic and overseas markets. Inscobee's group turover was 57.8 billion Korean Won (USD 52.2m) last year and they are curently focused on expanding the health supplement area of their business.

Inscobee sell and promote nutraceuticals through hospitals and a consumer distribution base through Korean off-line channels such as Holland & Barrett stores, hypermarkets, home-shopping, and e-commerce channels including on-line malls, open markets, influencer markets and live commerce markets.

This agreement with Inscobee is another milestone in a series of deals which ProBiotix have entered into within Asia which help build LP LDL(R) and CholBiome's reputation and brand awareness in the region and open up the potentail for cross boarder e-commerce trading in China. ProBiotix Health has substantial momentum in the region, according to a recent article published in Nutraingredient Asia: Probiotics and CVD: OptiBiotix extends CholBiome range to APAC as blood pressure and cholesterol concerns rise (nutraingredients-asia.com) .

Mr. Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health commened: "Incobee is the ideal partner in the fast moving, highly dynamic and competitive South Korean health food markets where consumers seek innovative and effective natural solutions which stand out in the market. We welcome Inscobee into a global team of CholBiome(R) distributors serving medical doctors and cardiovascular specialists and directly to consumers via homeshopping, pharmacies and medical clinics. By entering deals on CholBiome(R) and LP LDL(R) in India, China, Malaysia, Singapore, Indonesia, Phillipines, Taiwan, Australia, and New Zealand, ProBiotix is growing sales and developing a brand presence in these strategically important Asian growth markets."

Mr. Seung-Hyeon Nam, Director of Inscobee Plc, commented: "At Inscobee, we are very pleased to introduce CholBiome(R) products to the Korean healthcare market. We believe CholBiome(R) has great potential to fill the void of safe and beneficial cardiovascular health needs in the nation and expect that it will play a big role as a flaghship product of Inscobee's healthcare business. We look forward to a long and successful partnership with ProBiotix Health."

For further information, please contact:

   OptiBiotix Health plc                      www.optibiotix.com 
    Neil Davidson, Chairman                  Contact via Walbrook 
    Stephen O'Hara, Chief Executive 
    Cenkos Securities plc (Broker)             Tel: 020 7397 8900 
    Callum Davidson / Neil McDonald 
    Michael Johnson / Russell Kerr (Sales) 
    Walbrook PR Ltd                            Mob: 07876 741 001 
    Anna Dunphy 
   About OptiBiotix - www.optibiotix.com 
   OptiBiotix Health plc (AIM: OPTI), which was formed in March 
   2012, brings science to the development of compounds which 
   modify the human microbiome - the collective genome of the 
   microbes in the body - in order to prevent and manage human 
   disease and promote wellness. 
   OptiBiotix has an extensive R&D programme working with leading 
   academics in the development of microbial strains, compounds, 
   and formulations which are used as active ingredients and 
   supplements. More than twenty international food and healthcare 
   supplement companies have signed agreements with OptiBiotix 
   to incorporate their human microbiome modulators into a 
   wide range of food products and drinks. 
   OptiBiotix is also developing its own range of consumer 
   supplements and health products. The Company's current areas 
   of focus include obesity, cardiovascular health, and diabetes. 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

July 06, 2021 02:00 ET (06:00 GMT)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Optibiotix Health Charts.
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Optibiotix Health Charts.